Page 76 - GTM-3-2

Global Translational Medicine Genes and blood cells in Ph-negative MPNs

plasminogen activators and urokinase receptor in platelet and polycythemia vera patients. Blood. 2011;118:2599-2601.
kinetics. Hematol J. 2000;1(3):199-205.
doi: 10.1182/blood-2011-02-339655
doi: 10.1038/sj.thj.6200029
46. Zini R, Guglielmelli P, Pietra D, et al. CALR mutational
44. Mejía-Ochoa M, Acevedo Toro PA, Cardona-Arias JA. status identifies different disease subtypes of essential
Systematization of analytical studies of polycythemia vera, thrombocythemia showing distinct expression profiles.
essential thrombocythemia and primary myelofibrosis, and Blood Cancer J. 2017;7:638.
a meta-analysis of the frequency of JAK2, CALR and MPL
mutations: 2000–2018. BMC Cancer. 2019;19:590. doi: 10.1038/s41408-017-0010-2
doi: 10.1186/s12885-019-5764-4 47. Thomas S, Krishnan A. Platelet heterogeneity in
myeloproliferative neoplasms. Arterioscler Thromb Vasc
45. Panova-Noeva M, Marchetti M, Buoro S, et al. JAK2V617F
mutation and hydroxyurea treatment as determinants of Biol. 2021;41(11):2661-2670.
immature platelet parameters in essential thrombocythemia doi: 10.1161/ATVBAHA.121.316373

Volume 3 Issue 2 (2024) 12 doi: 10.36922/gtm.2559